Skip to main content
Premium Trial:

Request an Annual Quote

NCI to Evaluate Ciphergen s Protein Microarray in Ovarian Cancer Studies

NEW YORK, April 28 (GenomeWeb News) - The US National Cancer Institute will evaluate Cipergen's ProteinChip platform as part of an effort to identify technology capable of detecting protein patterns that can classify cancer states, Ciphergen said today.

 

The NCI Clinical Proteomics Reference Laboratory will examine the company's ProteinChip Series 4000 platform, as well as associated arrays and bioinformatics suites, to study biomarker patterns indicative of ovarian cancer, the company said.

 

The company did not disclose any financial details associated with the agreement.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.